Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approval for Metvix

July 30, 2004

Endovasc updates pipeline progress

July 30, 2004

Phase I results of spi-VEC vaccine for hepatitis B

July 30, 2004

GSK researchers design novel thrombin/factor Xa inhibitors

July 30, 2004

Novel VEGFR inhibitors prepared and tested by ImClone researchers

July 30, 2004

New PTP-1B inhibitors described by Wyeth researchers

July 30, 2004

New orexin-2 antagonists and their use in obesity and sleep disorders

July 30, 2004

Novel antitumor and antifungal compounds developed at Gemin X

July 30, 2004

New factor VIIa/TF inhibitors under study at Schering AG

July 30, 2004

Chinese researchers identify novel agents for renal disorders

July 30, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...